12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Daratumumab regulatory update

FDA granted Fast Track designation for Genmab's daratumumab to treat multiple myeloma (MM) in patients who have received >=3 prior lines of therapy, including a...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >